Skip to main content
Top
Published in: Current Rheumatology Reports 8/2016

01-08-2016 | Pediatric Rheumatology (M Stoll, Guest Section Editor)

Juvenile Spondyloarthropathies

Authors: Amra Adrovic, Kenan Barut, Sezgin Sahin, Ozgur Kasapcopur

Published in: Current Rheumatology Reports | Issue 8/2016

Login to get access

Abstract

Juvenile spondyloarthropathies represent a clinical entity separate from the adult disease. Initial clinical signs of juvenile spondyloarthropathies often include lower extremity arthritis and enthesopathy, without axial involvement at the disease onset. Asymmetrical oligoarthritis of lower extremities is typically seen in this type of arthritis. Enthesopathy, which is the hallmark of the disease, is most commonly seen in the Achilles tendon, being manifested by heel pain. Anterior uveitis and HLA-B27 positivity are seen in a proportion of cases. Sacroiliitis is generally asymptomatic in the pediatric population. Ineffective treatment of childhood disease results in disease progression to typical adult form of ankylosing spondylitis. Therefore, early diagnosis and classification remains one of the most relevant questions in pediatric rheumatology. It should be kept in mind that the disease could be misdiagnosed as FMF or Behçet’s syndrome in countries with a high incidence of those conditions. This review revises available classification criteria, clinical manifestations and therapeutic options for patients with juvenile spondyloarthropathies.
Literature
1.••
go back to reference Tse SML, Laxer RM. New advances in juvenile spondyloarthritis. Nat Rev Rheumatol. 2012;8:269–79. An up-to date review of advances in the classification, diagnosis and management strategies for juvenile spondyloarthritis.CrossRefPubMed Tse SML, Laxer RM. New advances in juvenile spondyloarthritis. Nat Rev Rheumatol. 2012;8:269–79. An up-to date review of advances in the classification, diagnosis and management strategies for juvenile spondyloarthritis.CrossRefPubMed
2.
go back to reference Kasapcopur O, Ayaz AN, Apelyan M, Ozdogan H, Arisoy N. Juvenile-onset Spondyloarthropathies. Current Options in Pediatric Rheumatology. A guide for general practitioners and pediatricians. New York: Nova Science Publisher; 2006. Kasapcopur O, Ayaz AN, Apelyan M, Ozdogan H, Arisoy N. Juvenile-onset Spondyloarthropathies. Current Options in Pediatric Rheumatology. A guide for general practitioners and pediatricians. New York: Nova Science Publisher; 2006.
3.
go back to reference Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
4.••
go back to reference Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:1–44. Fundamental manuscript on the most relevant aspects for the assessment of spondyloarthritis. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:1–44. Fundamental manuscript on the most relevant aspects for the assessment of spondyloarthritis.
5.
go back to reference Kasapcopur O, Demirli N, Ozdogan H, Apelyan M, Caliskan S, Sever L, et al. Evaluation of classification criteria for juvenile-onset spondyloarthropathies. Rheumatol Int. 2004;25:414–8.CrossRefPubMed Kasapcopur O, Demirli N, Ozdogan H, Apelyan M, Caliskan S, Sever L, et al. Evaluation of classification criteria for juvenile-onset spondyloarthropathies. Rheumatol Int. 2004;25:414–8.CrossRefPubMed
6.
go back to reference Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseses: results from the Canadian pediatric rheumatology association disease registry. J Rheumatol. 1996;23:1981–7.PubMed Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseses: results from the Canadian pediatric rheumatology association disease registry. J Rheumatol. 1996;23:1981–7.PubMed
7.
go back to reference Oen K, Fast M, Postl BL. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada: cycles in incidence. J Rheumatol. 1995;22:745–50.PubMed Oen K, Fast M, Postl BL. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada: cycles in incidence. J Rheumatol. 1995;22:745–50.PubMed
8.
go back to reference Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. CARRA Registry Investigators Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2012;39:2341–51.CrossRefPubMedPubMedCentral Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. CARRA Registry Investigators Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2012;39:2341–51.CrossRefPubMedPubMedCentral
9.
go back to reference Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39:1867–74.CrossRefPubMedPubMedCentral Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39:1867–74.CrossRefPubMedPubMedCentral
10.
go back to reference Kasapçopur O, Yologlu N, Ozyazgan Y, Ercan G, Caliskan S, Sever L, et al. Uveitis and anti nuclear antibody positivity in children with juvenile idiopathic arthritis. Indian Pediatr. 2004;41:1035–9.PubMed Kasapçopur O, Yologlu N, Ozyazgan Y, Ercan G, Caliskan S, Sever L, et al. Uveitis and anti nuclear antibody positivity in children with juvenile idiopathic arthritis. Indian Pediatr. 2004;41:1035–9.PubMed
11.
go back to reference Ozdogan H, Kasapcopur O, Dede H, Arisoy N, Beceren T, Yurdakul S, et al. Juvenile chronic arthritis in a Turkish population. Clin Exp Rheumatol. 1991;9:431–5.PubMed Ozdogan H, Kasapcopur O, Dede H, Arisoy N, Beceren T, Yurdakul S, et al. Juvenile chronic arthritis in a Turkish population. Clin Exp Rheumatol. 1991;9:431–5.PubMed
12.•
go back to reference Demirkaya E, Ozen S, Bilginer Y, Ayaz N, Makay B, Unsal E, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol. 2011;29:111–6. A relevant cross-sectional study of demographics, clinical and laboratory features and subtype distribution of juvenile idiopathic arthritis in an eastern Mediterranean country, based on a multicenter registry.PubMed Demirkaya E, Ozen S, Bilginer Y, Ayaz N, Makay B, Unsal E, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol. 2011;29:111–6. A relevant cross-sectional study of demographics, clinical and laboratory features and subtype distribution of juvenile idiopathic arthritis in an eastern Mediterranean country, based on a multicenter registry.PubMed
13.
14.••
go back to reference Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34:1839–46. Brief description of the pathogenesis, clinical features and treatment options for enthesitis-related arthritis.CrossRefPubMed Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34:1839–46. Brief description of the pathogenesis, clinical features and treatment options for enthesitis-related arthritis.CrossRefPubMed
15.
go back to reference Jacques P, Elewaut D. Gut inflammation in SpA: flagellin joins the dance? Nat Rev Rheumatol. 2014;10:5–6.CrossRefPubMed Jacques P, Elewaut D. Gut inflammation in SpA: flagellin joins the dance? Nat Rev Rheumatol. 2014;10:5–6.CrossRefPubMed
16.
go back to reference Sezen M, Barut K, Açıkel C, Kasapcopur O. The new proposal classification criteria for juvenile spondyloarthropathies [abstract]. Arthritis Rheumatol. 2014;66:S1004(2301) (suppl 10). Sezen M, Barut K, Açıkel C, Kasapcopur O. The new proposal classification criteria for juvenile spondyloarthropathies [abstract]. Arthritis Rheumatol. 2014;66:S1004(2301) (suppl 10).
18.•
go back to reference Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31. Comparison of The Assessment of Spondylo Arthritis International Societ (ASAS) classification criteria with the European Spondylarthropathy Study Group (ESSG) and Amor criteria which shows that the new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis.CrossRefPubMed Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31. Comparison of The Assessment of Spondylo Arthritis International Societ (ASAS) classification criteria with the European Spondylarthropathy Study Group (ESSG) and Amor criteria which shows that the new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis.CrossRefPubMed
19.•
go back to reference Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83. ASAS report that validates and refines two sets of criteria for the classification and diagnosis of axial spondyloarthritis.CrossRefPubMed Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83. ASAS report that validates and refines two sets of criteria for the classification and diagnosis of axial spondyloarthritis.CrossRefPubMed
20.••
go back to reference Burgos-Vargas R. The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: a critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol. 2012;10:14. Excellent assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis with a special emphasis on the pediatric population.CrossRef Burgos-Vargas R. The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: a critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol. 2012;10:14. Excellent assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis with a special emphasis on the pediatric population.CrossRef
21.•
go back to reference Duartea AP, Marquesa CDL, Bortoluzzob AB, Goncalvesc CR, da Silvad JA B, Ximenese AC, et al. Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort. Rev Bras Reumatol. 2014;54:424–30. Prospective, multicenter analysis of a large Brazilian cohort with 1424 patients with the diagnosis of SpA revealing the main differences among juvenile-onset and adult-onset spondyloarthritis patients.CrossRef Duartea AP, Marquesa CDL, Bortoluzzob AB, Goncalvesc CR, da Silvad JA B, Ximenese AC, et al. Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort. Rev Bras Reumatol. 2014;54:424–30. Prospective, multicenter analysis of a large Brazilian cohort with 1424 patients with the diagnosis of SpA revealing the main differences among juvenile-onset and adult-onset spondyloarthritis patients.CrossRef
22.
go back to reference Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD, et al. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum. 2005;53:445–51.CrossRefPubMed Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD, et al. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum. 2005;53:445–51.CrossRefPubMed
23.
go back to reference Alvarez-Madrid C, Merino R, Inocencio JD, Garcia-Consuegra J. Tarsitis as an initial manifestation of juvenile spondyloarthropathy. Clin Exp Rheumatol. 2009;27:691–4.PubMed Alvarez-Madrid C, Merino R, Inocencio JD, Garcia-Consuegra J. Tarsitis as an initial manifestation of juvenile spondyloarthropathy. Clin Exp Rheumatol. 2009;27:691–4.PubMed
24.
go back to reference Barut K, Sezen M, Sahin S, Adrovic A, Ugurlu S, Ozdogan H, et al. Juvenile Spondyloarthropathies: a Single Center Experience [abstract]. Ann Rheum Dis. 2015;74 suppl 2:390.CrossRef Barut K, Sezen M, Sahin S, Adrovic A, Ugurlu S, Ozdogan H, et al. Juvenile Spondyloarthropathies: a Single Center Experience [abstract]. Ann Rheum Dis. 2015;74 suppl 2:390.CrossRef
25.
go back to reference van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811–8.CrossRefPubMed van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811–8.CrossRefPubMed
26.
go back to reference Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, Dewitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res. 2014;66:1775–82.CrossRef Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, Dewitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res. 2014;66:1775–82.CrossRef
27.
go back to reference Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum. 2007;56:1974–84.CrossRefPubMed Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum. 2007;56:1974–84.CrossRefPubMed
28.
go back to reference Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE, Lo MS, et al. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016;14:9.CrossRefPubMedPubMedCentral Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE, Lo MS, et al. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016;14:9.CrossRefPubMedPubMedCentral
29.
go back to reference Kahn P. Juvenile idiopathic arthritis. An update for the clinican. Bull NYU Hosp Jt Dis. 2012;70:152–66.PubMed Kahn P. Juvenile idiopathic arthritis. An update for the clinican. Bull NYU Hosp Jt Dis. 2012;70:152–66.PubMed
30.
go back to reference Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies. Clin Exp Rheumatol. 2002;20:727–31.PubMed Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies. Clin Exp Rheumatol. 2002;20:727–31.PubMed
31.
go back to reference Berntson L, Damgard M, Andersson-Gare B, Herlin T, Nielsen S, Nordal E, et al. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol. 2008;35:2055–61.PubMed Berntson L, Damgard M, Andersson-Gare B, Herlin T, Nielsen S, Nordal E, et al. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol. 2008;35:2055–61.PubMed
32.
go back to reference Saraux A, Benichou J, Guillevin L, Idbrik L, Job-Deslandre C, Sibilia J, et al. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France?The CORPUS cohort study. Clin Exp Rheumatol. 2015;33:602–10.PubMed Saraux A, Benichou J, Guillevin L, Idbrik L, Job-Deslandre C, Sibilia J, et al. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France?The CORPUS cohort study. Clin Exp Rheumatol. 2015;33:602–10.PubMed
33.
go back to reference Helliwell PS. Relationship of psoriatic arthritis with the other spondyloarthropathies. Curr Opin Rheumatol. 2004;16:344–9.CrossRefPubMed Helliwell PS. Relationship of psoriatic arthritis with the other spondyloarthropathies. Curr Opin Rheumatol. 2004;16:344–9.CrossRefPubMed
34.•
go back to reference Ravelli A, Consolaro A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis. Clin Exp Rheumatol. 2015;33:40–3. A worthy manuscript which debates discordances in the definition and classification of juvenile psoriatic arthritis. Ravelli A, Consolaro A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis. Clin Exp Rheumatol. 2015;33:40–3. A worthy manuscript which debates discordances in the definition and classification of juvenile psoriatic arthritis.
35.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed
36.•
go back to reference Vendhan K, Sen D, Fisher C, Ioannou Y, Hall-Cragg MA. Inflammatory changes of the lumbar spine in children and adolescents with enthesitis-related arthritis: magnetic resonance imaging findings. Arthritis Care Res. 2014;66:40–6. A considerable description of magnetic resonance imaging of lumbar spine abnormalities in a cohort of patients with enthesitis-related arthritis compared to a control group of adolescents with mechanical back pain.CrossRef Vendhan K, Sen D, Fisher C, Ioannou Y, Hall-Cragg MA. Inflammatory changes of the lumbar spine in children and adolescents with enthesitis-related arthritis: magnetic resonance imaging findings. Arthritis Care Res. 2014;66:40–6. A considerable description of magnetic resonance imaging of lumbar spine abnormalities in a cohort of patients with enthesitis-related arthritis compared to a control group of adolescents with mechanical back pain.CrossRef
37.
go back to reference Yilmaz MH, Ozbayrak M, Kasapcopur O, Kurugoglu S, Kanberoglu K. Pelvic MRI findings of juvenile-onset ankylosing spondylitis. Clin Rheumatol. 2010;29:1007–13.CrossRefPubMed Yilmaz MH, Ozbayrak M, Kasapcopur O, Kurugoglu S, Kanberoglu K. Pelvic MRI findings of juvenile-onset ankylosing spondylitis. Clin Rheumatol. 2010;29:1007–13.CrossRefPubMed
38.
go back to reference Weiss PF, Xiao R, Biko DM, Johnson AM, Chauvin NA. Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary? Arthritis Rheumatol. 2015;67:2250–6.CrossRefPubMedPubMedCentral Weiss PF, Xiao R, Biko DM, Johnson AM, Chauvin NA. Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary? Arthritis Rheumatol. 2015;67:2250–6.CrossRefPubMedPubMedCentral
39.
go back to reference Pagnini I, Savelli S, Matucci-Cerinic M, Fonda C, Cimaz R, Simonini G. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol. 2010;37:2395–401.CrossRefPubMed Pagnini I, Savelli S, Matucci-Cerinic M, Fonda C, Cimaz R, Simonini G. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol. 2010;37:2395–401.CrossRefPubMed
40.
go back to reference Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465–82.CrossRef Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465–82.CrossRef
41.
go back to reference Paramarta JE, Baeten D. Spondyloarthritis: from unifying concepts to improved treatment. Rheumatology (Oxford). 2014;53:1547–59.CrossRef Paramarta JE, Baeten D. Spondyloarthritis: from unifying concepts to improved treatment. Rheumatology (Oxford). 2014;53:1547–59.CrossRef
42.
go back to reference Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, et al. Double-blind, placebocontrolled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;24:R230.CrossRef Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, et al. Double-blind, placebocontrolled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;24:R230.CrossRef
43.
go back to reference Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981–91.CrossRefPubMed Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981–91.CrossRefPubMed
44.
go back to reference Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73:101–7.CrossRefPubMed Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73:101–7.CrossRefPubMed
45.
go back to reference Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276–81.CrossRefPubMed Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276–81.CrossRefPubMed
46.•
go back to reference Canoui Poitrine F, Poulain C, Molto A, Le T, Lafon C, Farrenq V, et al. Early tumor necrosis factor-antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res (Hoboken). 2014;66:1395–402. Data from a French prospective observational study that underlines the importance of early diagnosis and treatment of axial spondyloarthritis in order to achieve the best improvement of patient symptoms. Furthermore, it defines factors associated with early anti-TNF alpha initiation.CrossRef Canoui Poitrine F, Poulain C, Molto A, Le T, Lafon C, Farrenq V, et al. Early tumor necrosis factor-antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res (Hoboken). 2014;66:1395–402. Data from a French prospective observational study that underlines the importance of early diagnosis and treatment of axial spondyloarthritis in order to achieve the best improvement of patient symptoms. Furthermore, it defines factors associated with early anti-TNF alpha initiation.CrossRef
47.
go back to reference Baeten D, Sieper J, Braun J, Sieper J, Emery P, van der Heijde D. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–13.CrossRefPubMed Baeten D, Sieper J, Braun J, Sieper J, Emery P, van der Heijde D. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–13.CrossRefPubMed
48.
go back to reference McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-tosevere psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349–56.CrossRefPubMed McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-tosevere psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349–56.CrossRefPubMed
49.
go back to reference Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, doubleblind, placebo controlled, crossover trial. Lancet. 2009;373:633–40.CrossRefPubMed Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, doubleblind, placebo controlled, crossover trial. Lancet. 2009;373:633–40.CrossRefPubMed
50.
go back to reference McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;31:780–9.CrossRef McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;31:780–9.CrossRef
51.•
go back to reference Hugle B, Burgos-Vargas R, Inman RD, O’Shea F, Laxer RM, Stimec J, et al. Long-term outcome of anti-tumour necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. 2014;32:424–31. An observational study of 16 patients with JSpA from 3 centers that describes long-term efficacy of anti-TNF treatment in JSpA refractory to standard therapy.PubMed Hugle B, Burgos-Vargas R, Inman RD, O’Shea F, Laxer RM, Stimec J, et al. Long-term outcome of anti-tumour necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. 2014;32:424–31. An observational study of 16 patients with JSpA from 3 centers that describes long-term efficacy of anti-TNF treatment in JSpA refractory to standard therapy.PubMed
52.
go back to reference Jadon D, Shaddick G, Jobling A, Ramanan AV, Sengupta R. Clinical outcomes and progression to orthopedic surgery in juvenile versus adult onset ankylosing spondylitis. Arthritis Care Res (Hoboken). 2015;67:651–7.CrossRef Jadon D, Shaddick G, Jobling A, Ramanan AV, Sengupta R. Clinical outcomes and progression to orthopedic surgery in juvenile versus adult onset ankylosing spondylitis. Arthritis Care Res (Hoboken). 2015;67:651–7.CrossRef
53.
go back to reference Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69:138–42.CrossRefPubMed Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69:138–42.CrossRefPubMed
54.
go back to reference Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145–52.CrossRefPubMed Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145–52.CrossRefPubMed
55.
go back to reference Conway R, O'shea FD. Juvenile versus adult-onset ankylosing spondylitis: are we comparing apples and oranges? J Rheumatol. 2012;39:887–9.CrossRefPubMed Conway R, O'shea FD. Juvenile versus adult-onset ankylosing spondylitis: are we comparing apples and oranges? J Rheumatol. 2012;39:887–9.CrossRefPubMed
56.
go back to reference Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005;52:2103–8.CrossRefPubMed Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005;52:2103–8.CrossRefPubMed
Metadata
Title
Juvenile Spondyloarthropathies
Authors
Amra Adrovic
Kenan Barut
Sezgin Sahin
Ozgur Kasapcopur
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 8/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0603-y

Other articles of this Issue 8/2016

Current Rheumatology Reports 8/2016 Go to the issue

Health Economics and Quality of Life (M Harrison, Section Editor)

Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences

Scleroderma (J Varga, Section Editor)

Erectile Dysfunction in Systemic Sclerosis

Vasculitis (LR Espinoza, Section Editor)

Neuromyelitis Optica (Devic’s Syndrome): an Appraisal

Osteoarthritis (MB Goldring, Section Editor)

The Role of MicroRNAs and Their Targets in Osteoarthritis

Health Economics and Quality of Life (M Harrison, Section Editor)

Economic Theory and Self-Reported Measures of Presenteeism in Musculoskeletal Disease